Investigating the effect of combined use of selenium and Myo-inositol supplements on thyroid function and autoimmune characteristics in thyroid disorders: a systematic review and meta-analysis

ABSTRACT

Background

This study aimed to systematically review the effect of selenium and inositol combination on thyroid function, autoimmune characteristics in thyroid diseases.

Research design and methods

To identify eligible studies, a systematic search was conducted in the PubMed/MEDLINE, Science-Direct, CINHAL, EMBASE, SCOPUS, Psychinfo, Cochrane, ProQuest, and Web of Science were searched using the main concepts, and all English-written articles that were published between 2007 and 2022 and had an available full text were examined.

Results

The data analysis of this research revealed that after the simultaneous use of selenium and inositol supplements, the level of Triiodothyronine(T3) increased by 0.105 in patients with thyroid disorders although this increase was not significant (P-value: 0.228). The level of Thyroxine (T4) significantly increased by 0.06 (P-value: 0.04). Anti-Thyroid Peroxidase Antibody (TPOAb) titer decreased by 119.36%, which was not significant (P-value: 0.070). Finally, the level of Thyroid-stimulating hormone (TSH) decreased by 1.45%, which was a significant change (P-value: 0.001).

Conclusion

It was observed that simultaneous use of selenium and inositol supplements did not change the T3 and TPOAb titer levels; however, it leads to a decrease in TSH and increase in T4 levels. Further studies are required due to the limited number of studies.

KEYWORDS:

• Thyroglobulin antibody
• thyroid peroxidase antibody
• CXCL10
• selenium
• inositol

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/17446651.2023.2295487.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgments

The researchers thank the Endocrine and Metabolism Research Center of Isfahan University of Medical Sciences for approving the current research project with the code 2401229.

Ethics statement

The present study is part of the research project approved by Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences with ethics code of IR.ARI.MUI.REC.1401.276.All methods were carried out in accordance with relevant guidelines and regulations.

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials. If you need more data that support the findings of this study are available on request from the corresponding author by e-mail.

Author contribution statement

All authors should have contributed to the conception and design of the review article and interpreting the relevant literature, and been involved in writing the review article or revised it for intellectual content. Maryam Sadat Hashemi wrote the first draft of this study Maryam Yavari, Mojtaba Akbari, Amirhossein Ramezani Ahmadi, Mansour Siavash Dastjerdi reviewed the first draft of the manuscript. Articles were imported from PUBMED/MEDLINE, Science-Direct, CINAHL, EMBASE, SCOPUS, Cochrane into ENDNOTE by M. Akbari. Two reviewers (M. Hashemi and M. Akbari) independently screened the remaining records, first by title and then by abstracts. For studies that fulfilled the inclusion criteria, two review authors (M. Hashemi and M. Akbari) independently extracted relevant population and intervention characteristics onto a predesigned template. Where there were further questions regarding one or more of the included trials, an e-mail request was sent to the corresponding author of the study. Quality of evidence was assessed per outcome, independently by two reviewers (M. Hashemi and M. Yavari) by using the GRADE guidelines for rating the quality of evidence. The Cochrane risk-of-bias tool was used by M. Yavari and M. Akbari. Differences of opinion were resolved by discussion and consensus. M. Akbari and Amirhossein Ramezani Ahmadi involved in the data analysis phase. All authors have read and approved the final version of the manuscript. All authors agreed on the journal to which the article will be submitted and they reviewed and agreed on all versions of the article before submission, during revision, the final version accepted for publication, and any significant changes introduced at the proofing stage. Also they agree to take responsibility and be accountable for the contents of the article and to share responsibility to resolve any questions raised about the accuracy or integrity of the published work.

Notes

1. Hashimoto’s thyroiditis (HT).

2. Thyroid-stimulating hormone(TSH).

3. Anti-Thyroid Peroxidase Antibody (TPOAb).

4. Autoimmune Thyroiditis (AT).

5. Free Serum T4(FT4).

6. Not Significant (NS).

7. Free Serum 3(FT3).

8. C-X-C motif chemokine ligand 10 (CXCL10).

9. Not Reported (NR).

10. Subclinical Hypothyroidism (SCH).

Additional information

Funding

This manuscript was funded by Isfahan University of Medical Sciences, Isfahan, Iran (Grant no: 2401229).